Clinical Trial

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Study acronym: FDG Immun Comb
Recruiting
View on ClinicalTrials.gov →
Summary
The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated or not with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-13; most recent amendment 2026-05-27.
Trial Details
NCT Number NCT06833229
Lead Sponsor Centre Antoine Lacassagne
Conditions Carcinoma, Non-Small-Cell Lung (NSCLC)
Enrollment 200 participants
Start Date 2022-01-27
Primary Completion 2028-05-27 (estimated)
Study Completion 2031-01-27 (estimated)
Updated on ClinicalTrials.gov 2026-05-29